Harvard Bioscience earnings release, May 12, 2026

Harvard Bioscience Inc (HBIO) · Form 8-K, Item 2.02 · Filed · SEC filing

Harvard Bioscience Announces

First

Quarter

2026

Financial

Results

HOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience,

Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the first quarter ended March 31, 2026.

“First quarter revenues were in line with our expectations and gross margin expanded year-over-year, while we remained profitable on an adjusted EBITDA basis,” said John Duke, President and Chief Executive

Officer. “We are encouraged by the adoption rates of our NPI portfolio – specifically the MeshMEA

TM organoid platform, and our BTX® Electroporation and SoHo™ Telemetry systems – which are deepening our reach into the biopharma sector. This shift toward a higher-margin product mix is expected to put us on a path toward consistent 60+% margin and higher recurring revenue. Additionally, our manufacturing consolidation is on track and is expected to yield significant efficiencies and cost savings. Looking ahead, we continue to focus on operational efficiency and believe we remain well positioned for our next phase of growth. We’re reaffirming our full year guidance, which anticipates high margin NPI sales growth driving bottom line growth in the second half of the year.”

First

Quarter 2026

Results

For the first quarter of 2026, the Company reported revenues of $20.8 million compared to $21.8 million in the first quarter of 2025. Gross margin for the first quarter of 2026 was 59%, compared to 56% in the first quarter of 2025.

Net loss for the first quarter of 2026 was $(3.4) million, compared to a net loss of $(50.3) million in the first quarter of 2025, which included goodwill impairment of $(48.0) million. Adjusted EBITDA for the first quarter of 2026 was $0.8 million compared to $0.8 million in the first quarter of the prior year. Cash (used) in and provided by operations was $(0.7) million during the three months ended March 31, 2026, compared to $3.0 million in the same period in 2025. The reduction in the cash balance is primarily due to one-time charges related to the process that resulted in the debt refinancing.

This press release includes certain financial information presented on an adjusted, or non-GAAP, basis. For additional information on the non-GAAP financial measures included in this press release, see

“Use of Non-GAAP Financial Information” and “Reconciliation of GAAP to Non-GAAP Financial Measures” below.

Second Quarter 2026 Guidance

The Company’s Q2 outlook reflects year-over-year revenue growth in the mid-single digit range at the midpoint of guidance, margin expansion as NPI adoption scales, and continued profitability on an adjusted EBITDA basis. We expect:

Full Year 2026 Guidance

The Company is reaffirming its full-year guidance and anticipates a ramp in revenue in the second half of the year, driven by expected sales growth in our higher margin NPI pipeline, which includes products for organoids and electroporation. The Company continues to expect:

Webcast and Conference Call Details

In conjunction with this announcement, Harvard Bioscience will be hosting a conference call and webcast today at 8:00 a.m. Eastern Time. A presentation that will be referenced during the webcast will be posted to the Company’s Investor Relations website shortly before the webcast begins.

Analysts who would like to join the call and ask a question must register here

(https://register-conf.media-server.com/register/BIec8b2ff5898f4554a258f5a3be030ad5).

Once registered, you will receive the dial-in numbers and a unique PIN number.

Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here

(https://investor.harvardbioscience.com/events-and-presentations).

Use of Non-GAAP Financial

Information

In this press release we have included non-GAAP financial information, including one or more of adjusted operating income (loss), adjusted operating margin, adjusted gross margin, adjusted net income (loss), adjusted EBITDA, adjusted EBITDA margin, diluted adjusted earnings (loss) per share, and net debt. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of our business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income resulting from items that we do not believe are reflective of the underlying operations of the business. Items excluded include stock-based compensation, amortization of intangibles related to acquisitions, restructuring charges, other operating expenses, goodwill impairment, interest and other expense, net, loss on pension settlement, loss on equity securities, income taxes, and the tax impact of reconciling items. Management believes that this non-GAAP financial information is important in comparing current results with prior period results and is useful to investors and financial analysts in assessing the

Company’s operating performance.

Historical non-GAAP financial information included herein is accompanied by a reconciliation to the nearest corresponding GAAP measure, which is included below.

The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different from other companies’ non-GAAP financial information.

About Harvard

Bioscience

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned... (truncated) laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations.

With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at www.harvardbioscience.com.

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended March 31, — (Unaudited, in thousands, except per share data)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Revenues20,75521,774
Cost of revenues8,5119,590
Gross profit12,24412,184
Sales and marketing expenses5,3354,971
General and administrative expenses4,7025,185
Research and development expenses2,3262,321
Amortization of intangible assets8201,160
Goodwill impairment47,951
Other operating expenses235264
Total operating expenses13,41861,852
Operating loss-1,174-49,668
Other expense:Interest expense-1,728-933
Other expense:Other expense, net-405-193
Other expense:Total other expense-2,133-1,126
Other expense:Loss before income taxes-3,307-50,794
Other expense:Income tax expense (benefit)117-454
Other expense:Net loss-3,424-50,340
Loss per share:Basic and diluted loss per share *-0.77-11.42
Weighted-average common shares:Basic and diluted *4,4734,410

Income Statement

Three Months Ended — (In thousands, except per share data and percentages)

Three Months Ended – March 31, 2026March 31, – 2026Three Months Ended – March 31, 2025March 31, – 2025
GAAP operating loss-1,174-49,668
Stock-based compensation257600
Acquired asset amortization8201,160
Goodwill impairment47,951
Other operating expenses (1)235264
Other adjustments9312
Adjusted operating income231319
Operating margin-5.7%-228.1%
Adjusted operating margin1.1%1.5%
GAAP net loss-3,424-50,340
Stock-based compensation257600
Acquired asset amortization8201,160
Goodwill impairment47,951
Other operating expenses (1)235264
Other adjustments9312
Income taxes525-199
Adjusted net loss-1,494-552
Depreciation & amortization536495
Interest and other expense, net (2)2,1331,126
Adjusted income taxes (3)-408-255
Adjusted EBITDA767814
Adjusted EBITDA margin3.7%3.7%
Diluted loss per share (GAAP) *-0.77-11.42
Diluted adjusted loss per share *-0.33-1.25
Weighted-average common shares:Diluted GAAP *4,4734,410
Weighted-average common shares:Diluted Adjusted *4,4734,410
Weighted-average common shares:Debt, including unamortized deferred financing costs36,21135,958
Weighted-average common shares:Unamortized deferred financing costs3,789392
Weighted-average common shares:Cash and cash equivalents-7,098-5,546
Weighted-average common shares:Net debt32,90230,804

Balance Sheet

December 31, — (Unaudited, in thousands)

March 31, – 2026December 31, – 2025
AssetsCash and cash equivalents7,0988,614
AssetsAccounts receivable, net14,57216,043
AssetsInventories22,20520,805
AssetsOther current assets3,6042,763
AssetsTotal current assets47,47948,225
AssetsProperty, plant and equipment4,8694,787
AssetsGoodwill and other intangibles16,27817,198
AssetsOther long-term assets9,3129,861
AssetsTotal assets77,93880,071
Liabilities and Stockholders' EquityOther current liabilities23,86321,960
Liabilities and Stockholders' EquityTotal current liabilities23,86321,960
Liabilities and Stockholders' EquityLong-term debt, net36,21135,870
Liabilities and Stockholders' EquityOther long-term liabilities7,8188,507
Liabilities and Stockholders' EquityStockholders’ equity10,04613,734
Liabilities and Stockholders' EquityTotal liabilities and stockholders’ equity77,93880,071

Cash Flow

Three Months Ended — (Unaudited, in thousands)

Three Months Ended – March 31, 2026Three Months Ended – March 31, 2025
Cash flows from operating activities:Net loss-3,424-50,340
Cash flows from operating activities:Adjustments to operating cash flows1,96849,814
Cash flows from operating activities:Changes in operating assets and liabilities7943,512
Cash flows from operating activities:Net cash (used in) provided by operating activities-6622,986
Cash flows from investing activities:Additions to property, plant and equipment-426-513
Cash flows from investing activities:Acquisition of intangible assets-194-170
Cash flows from investing activities:Net cash used in investing activities-620-683
Cash flows from financing activities:Repayment of term debt-1,000
Cash flows from financing activities:Payment of debt issuance costs-129-129
Cash flows from financing activities:Proceeds from exercise of employee stock options and purchases150
Cash flows from financing activities:Taxes paid related to net share settlement of equity awards-30-75
Cash flows from financing activities:Net cash used in financing activities-9-1,204
Cash flows from financing activities:Effect of exchange rate changes on cash and cash equivalents-225339
Cash flows from financing activities:(Decrease) increase in cash and cash equivalents-1,5161,438
Cash flows from financing activities:Cash and cash equivalents at the beginning of period8,6144,108
Cash flows from financing activities:Cash and cash equivalents at the end of period7,0985,546
Full release

This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,”

“estimate,” “intend,” “believe” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenues, adjusted gross margin, adjusted EBITDA, gross margin, cash and debt position, balance sheet, growth, adoption and the introduction of new products, the strength of the Company’s market position, business model and anticipated macroeconomic conditions. Forward-looking statements do not guarantee future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include those described in the “Risk

Factors” section of the Company’s most recently filed Annual Report on Form 10-K, as well as in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.

Investor Inquiries:

Mark Frost

Chief Financial Officer

(508) 893-3120 investors@harvardbioscience.com

HARVARD BIOSCIENCE, INC.

Condensed Consolidated Statements Of Operations

(Unaudited, in thousands, except per share data)

* Retroactively presented to reflect 1-for-10 reverse stock split effective on March 13, 2026.

HARVARD BIOSCIENCE, INC.

Condensed Consolidated Balance Sheets

(Unaudited, in thousands)

HARVARD BIOSCIENCE, INC.

Condensed Consolidated Statements Of Cash Flows

(Unaudited, in thousands)

HARVARD BIOSCIENCE, INC.

Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)

(In thousands, except per share data and percentages)

* Retroactively presented to reflect 1-for-10 reverse stock split effective on March 13, 2026.

(1) Other operating expenses for the three months ended March 31, 2026 includes $235 thousand of restructuring-related charges compared to $93 thousand of restructuring-related charges and $171 thousand of employee retention tax credit fees for the three months ended March 31, 2025.

(2) Interest expense for the three months ended March 31, 2026 was $1.7 million, compared to $0.9 million for the three months ended March 31, 2025. Other expense, net was $405 thousand for the three months ended March 31, 2026, compared to $193 thousand for the three months ended March 31, 2025.

(3) Adjusted income taxes includes the tax effect of adjusting for the reconciling items using the tax rates in the jurisdictions in which the reconciling items arise.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Harvard Bioscience earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.